In phase-II swine grower feed mills, botanical anthelmintic premixes containing Torreyae Semen are introduced through micro-dosing lines at low inclusion rates, where carrier particle-size mismatch becomes the dominant segregation risk. The API is a dried seed powder retaining a high free-oil fraction, commonly above 40.0% (w/w), and after hammer-milling through a 0.8 mm screen its particle-size distribution d(0.9) may exceed 250 µm. Uncompensated addition of such a lipid-rich powder to maize-soybean meal carriers produces vertical stratification in cones and horizontal drift in bucket elevators; therefore the material is first pre-blended with ground maize cob carrier at a 1:10 (w/w) API-to-carrier ratio, then diluted in 1:10 geometric steps until the registered final feed concentration is reached. Each dilution stage is mixed in a ribbon blender at 25–30 rpm for 10–15 min with vessel fill limited to 60–70% of gross capacity so that the batch does not superpose particle-size gradients. Raw-material identity is verified against the Semen Torreyae monograph of CP 2020 and USP <561> for botanical articles; phytochemical marker content is not used in lieu of full botanical identification. The process sequence from API intake to finished premix includes sifting through an 800 µm wire mesh, magnetic grid separation at 12,000 Gauss, loss-in-weight micro-dosing, and final mixer uniformity testing with 10 sampling points per batch. Compliance boundaries for this track are defined by 21 CFR 558.3 for U.S. medicated feed premixes, by Regulation (EU) 2019/6 where the product is registered as a veterinary herbal medicinal feed product, and by Regulation (EC) No 1831/2003 where the destination market classifies the product as a feed additive. Finished product types are low-inclusion meal premixes and pelleted feed concentrates for sequence feeding, with packaging in 25 kg multi-wall paper bags with polyethylene liners.

What keeps high-oil Torreyae Semen powder dispersible in poultry drinking water systems?

The free-oil content of the powdered seed material governs wetting behaviour when the API is dosed through Venturi-type drinking water medicators. Dry blending alone is insufficient because hydrophobic agglomerates form, float, and obstruct screen filters downstream of the in-line pump; the process remedy is wet granulation in a top-spray fluidized-bed processor. The granulating solution contains povidone K30 at 3.0–5.0% (w/w) of final granule mass and purified water; the API is pre-blended with lactose monohydrate and croscarmellose sodium at 2.0–4.0% (w/w) before fluidization. Product temperature during spraying is held at 38–42°C, and the final granule moisture is controlled at 3.0–5.0% (w/w) before classification through a 710 µm sieve. The finished granule is designed to remain dispersible for not less than 30 min in water of 500 ppm CaCO₃ hardness, although published dispersibility data for this specific botanical granule is limited and a pilot loading study must define the upper API load. Compliance testing uses USP <905> for dosage uniformity and USP <711> for dissolution or dispersion release where a veterinary granule monograph is absent; residual solvent and degradation product controls follow VICH GL18, and stability data are governed by VICH GL3. Terminal finished product types are 100 g and 1 kg foil-lined polyethylene terephthalate pouches of water-dispersible granules for continuous in-line dosing.

Encapsulation of Torreyae Semen powder for companion animal dosing is performed on intermittent capsule fillers where powder flow into the dosator is the primary batch-to-batch variable. A lipid-rich botanical powder compacts unevenly under tamping force and may leave an oil film on bronze bushings; the formulation therefore uses colloidal silicon dioxide at 0.5–1.0% (w/w) and microcrystalline cellulose PH102 at 20–30% (w/w) as flow modifiers, with API loading from 25–50% (w/w) depending on the registered capsule strength. Shell moisture is a compatibility boundary because hard gelatin and hypromellose capsules above 9.0% moisture may soften when in contact with the free-oil phase; desiccant silica gel packets at 1 g per 60 cm³ container volume are inserted to maintain headspace relative humidity below 45%. Blending is carried out in a V-type blender at 12–15 rpm for 15–20 min, and bulk powder content uniformity is confirmed by sampling 10 points before filling size 0 or size 1 capsules. The primary pharmacopoeial controls are USP <905> for content uniformity, USP <701> for disintegration, and USP <61>/<62> for microbial limits on botanical dosage forms; stability data are reported under VICH GL3. Finished product types are 250 mg and 500 mg capsules in polyvinyl chloride-aluminium blisters with desiccant enclosures.

Compression force limits in lipid-rich botanical matrices

Direct compression of Torreyae Semen is constrained by a processing window defined by punch cleanliness and tablet tensile strength, not by the absence of compressible excipients. The free-oil fraction migrates to the tablet surface during compression at elevated pressure and produces picking on stainless steel tooling after 30–60 min of continuous press operation unless the excipient system is adjusted. The compression blend contains microcrystalline cellulose PH102 at 30–40% (w/w), crospovidone at 2.0–4.0% (w/w), colloidal silicon dioxide at 0.5–1.0% (w/w), and magnesium stearate at 0.5–1.0% (w/w); API loading is maintained at 50–60% (w/w) for a 500 mg tablet, and published data for direct-compression loading above 70% (w/w) are limited. On a 16-station rotary press, compression force is set between 10 kN and 18 kN at turret speed 20–30 rpm, and upper punch penetration is trimmed to achieve hardness of 60–100 N while keeping friability below 1.0% under USP <1216>. Disintegration is tested in water at 37±2°C by USP <701>; dissolution is profiled with USP <711> apparatus II at 50 rpm in 0.1 M HCl with 0.5% sodium lauryl sulfate. Pre-drying of excipients is required when ambient relative humidity exceeds 60%, and lubrication time is limited to 3–5 min to avoid overlubrication. Compliance documentation includes 21 CFR 210/211 for finished pharmaceutical manufacturing, VICH GL3 for stability, and VICH GL18 for residual solvents. Finished product types are uncoated 250 mg and 500 mg tablets in high-density polyethylene bottles with induction seals.

When oral drench solutions replace in-feed premixes for pre-ruminant calves and lambs

For pre-ruminant calves and lambs, oral drench solutions are selected when feed intake cannot be relied on to deliver a uniform dose, but the lipophilic character of Torreyae Semen seed powder requires an emulsified or co-solvent vehicle rather than a simple aqueous suspension. The continuous phase is prepared from propylene glycol and purified water, with polysorbate 80 at 0.1–0.5% (w/w) as the emulsifier and xanthan gum at 0.2–0.3% (w/w) to control creaming; the API is dispersed at 1.0–5.0% (w/w) depending on the registered dose volume and species-specific target dose. Processing uses a high-shear rotor-stator mixer at 1,500–3,000 rpm for 10–15 min, followed by two-stage homogenization at 150/30 bar to reduce mean droplet diameter below 10 µm and stabilise the lipid phase. Bottle filling is conducted under nitrogen headspace to limit oxidative rancidity of the unsaturated oil fraction; when terminal sterilisation is not feasible, the finished product is pasteurised at 85–90°C for 30 min and filled aseptically. Compliance relies on VICH GL3 for stability studies, VICH GL18 for residual solvent control where ethanol extraction residues are present, and USP <785> for osmolality if large oral volumes are used in neonatal animals. Terminal finished product types are 100 mL and 250 mL amber glass drench bottles with tamper-evident caps.

Equine maintenance programmes may use an oral top-dress powder when the registered dose is delivered on a small meal rather than through a full feed premix. The API is micronized to d(0.9) below 150 µm and blended with lucerne meal and apple pomace carrier at a 1:4 (w/w) API-to-carrier ratio; the single-serve API content is derived from the species-specific dose divided by the 30 g sachet fill weight, typically occupying 10–20% (w/w). Palatability studies are required for each carrier lot because published data for repeated equine intake of this specific botanical are limited. Production is performed in a rotating drum mixer at 10 rpm for 20 min, at or below 25–30°C and 45% relative humidity, with sifting through a 500 µm mesh before sachet filling. Compliance follows VICH GL3 and the destination-market registration requirements for veterinary herbal powders; in the EU the product is classified as a veterinary medicinal product under Regulation (EU) 2019/6. Terminal finished product types are 30 g single-use sachets and 1 kg bulk top-dress packs.